We are live on ! Find out more
IMGN

Immunogen Inc

Delisted

IMGN was delisted on the 9th of February, 2024.

216 hedge funds and large institutions have $882M invested in Immunogen Inc in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 62 increasing their positions, 81 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

378% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $912K

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

0% less funds holding

Funds holding: 217216 (-1)

4% less capital invested

Capital invested by funds: $922M → $882M (-$39.6M)

23% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 81

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
216
Holders Change
-1
Holders Change %
-0.46%
% of All Funds
3.64%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
25
Increased
62
Reduced
81
Closed
23
Calls
$4.36M
Puts
$912K
Net Calls
+$3.45M
Net Calls Change
-$1.95M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$97.8M
State Street
2
State Street
Massachusetts
$81.9M +$19.5M +4,492,165 +33%
BlackRock
3
BlackRock
New York
$80.4M +$6.27M +1,444,336 +9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$72.3M +$2.52M +580,504 +4%
DM
5
Deerfield Management
New York
$67.6M +$50.2M +11,549,815 +333%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$52.1M
Wellington Management Group
7
Wellington Management Group
Massachusetts
$48.2M -$10.2M -2,346,399 -18%
RG
8
Redmile Group
California
$41.1M -$334K -76,900 -0.8%
Morgan Stanley
9
Morgan Stanley
New York
$24.7M +$1.05M +241,147 +5%
ClearBridge Investments
10
ClearBridge Investments
New York
$24.2M -$568K -130,778 -2%
Millennium Management
11
Millennium Management
New York
$22.8M +$6.76M +1,557,032 +44%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$16.6M +$853K +196,412 +6%
Deutsche Bank
13
Deutsche Bank
Germany
$13.6M +$370K +85,277 +3%
Two Sigma Advisers
14
Two Sigma Advisers
New York
$12.7M +$1.59M +364,900 +15%
MC
15
Maverick Capital
Texas
$12.4M +$12M +2,766,474 New
Northern Trust
16
Northern Trust
Illinois
$9.65M -$235K -54,108 -2%
Two Sigma Investments
17
Two Sigma Investments
New York
$9.12M -$262K -60,205 -3%
GIM
18
Granahan Investment Management
Massachusetts
$8.47M -$330K -75,923 -4%
Citadel Advisors
19
Citadel Advisors
Florida
$8.32M +$4.83M +1,112,373 +151%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$7.25M +$7M +1,611,076 New
Bank of America
21
Bank of America
North Carolina
$6.77M +$195K +44,817 +3%
TCM
22
Tang Capital Management
California
$6.75M
Charles Schwab
23
Charles Schwab
California
$6.59M -$156K -36,000 -2%
Renaissance Technologies
24
Renaissance Technologies
New York
$6.52M -$59.1K -13,600 -0.9%
PA
25
Pinnacle Associates
New York
$6.26M -$61.4K -14,136 -1%

IMGN Hedge Fund Activity: Q2 2022 in Review

216 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunogen Inc (IMGN) for Q2 2022, worth a combined $882M — down 4.3% from $922M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new IMGN positions and 23 closed out — a net gain of 2 holders — while 62 added to existing stakes and 81 trimmed.

The largest buyer was Deerfield Management, adding an estimated $50.2M. The largest seller was Fidelity Investments, cutting an estimated $47.7M.

  • 216 institutional investors held Immunogen Inc (IMGN) as of Q2 2022, down from 217 in Q1 2022.
  • Funds reported $882M of Immunogen Inc stock for Q2 2022, down 4.3% quarter-over-quarter.
  • 25 funds opened new Immunogen Inc positions in Q2 2022 and 23 closed out, a net change of +2 holders.
  • The largest Immunogen Inc buyer in Q2 2022 was Deerfield Management, an estimated $50.2M added.
  • The largest Immunogen Inc seller in Q2 2022 was Fidelity Investments, an estimated $47.7M sold.

Based on aggregated 13F filings for Q2 2022.